Ozempic Injection, Solution
Product Images NDC 50090-6051

101 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 101 technical images submitted to the FDA as part of the official labeling for Ozempic (NDC 50090-6051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural_formula (Image 01)

Structural_formula (Image 01)
Chemical structure diagram of semaglutide, the active ingredient in OZEMPIC 2.68 mg/mL subcutaneous injection. The diagram shows the peptide chain composition and the attached fatty acid moiety characteristic of semaglutide.*
FDA Label Image

Figure_1 (Image 02)

Figure_1 (Image 02)
A line graph depicting plasma glucose levels (mg/dL) over 24 hours since the start of a breakfast meal. The graph compares four groups: OZEMPIC 0.5 mg, OZEMPIC 1 mg, placebo baseline, and placebo, showing glucose fluctuations across time intervals in hours.*
FDA Label Image

Figure_2 (Image 03)

Figure_2 (Image 03)
A line graph showing insulin secretion rate (pmol/kg/min) plotted against plasma glucose levels (mg/dL). The graph compares multiple groups including baseline, subjects with CCI-IMF treatment and placebo, with separate lines for healthy subjects. Different markers and line styles represent each group across a plasma glucose range from 90 to 210 mg/dL.*
FDA Label Image

Figure_3 (Image 04)

Figure_3 (Image 04)
A chart depicting relative exposure (Cavg) ratios and 90% confidence intervals for semaglutide by intrinsic factors including sex, age, race, ethnicity, body weight, and renal impairment. The chart shows the comparison of semaglutide exposure relative to a reference subject profile, illustrating variations across categories such as male vs. female, age groups, racial and ethnic groups, different body weights, and levels of renal impairment.*
FDA Label Image

Figure_4 (Image 05)

Figure_4 (Image 05)
A chart titled 'Relative exposure Ratio and 90% CI' comparing the effects of various co-administered medications (Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, Levonorgestrel) on drug exposure. The chart shows relative exposure ratios around 1 with error bars, and a consistent recommendation of 'No dose adjustment' for all medications.*
FDA Label Image

Figure_5 (Image 06)

Figure_5 (Image 06)
A line graph comparing the percentage of HbA1c over time (weeks post randomization) among three groups: OZEMPIC 0.5 mg, OZEMPIC 1 mg, and Sitagliptin. The x-axis shows weeks from 0 to 56, and the y-axis shows HbA1c percentage ranging approximately from 6.0% to 8.5%. The graph includes data points and a table listing the number of patients per group at various time points.*
FDA Label Image

Figure_6 (Image 71)

Figure_6 (Image 71)
A line graph comparing the percentage of patients with an event over time in weeks, from randomization, for OZEMPIC (semaglutide) versus placebo. The y-axis shows patients with event (%) up to 10%, and the x-axis represents time from 0 to 109 weeks. Two lines indicate patient event percentages for OZEMPIC and placebo, with placebo consistently higher. Patient numbers at risk are shown below. The hazard ratio (HR) is 0.74 with a 95% confidence interval of 0.58 to 0.95.*
FDA Label Image

Image_121 (Image 07)

Image_121 (Image 07)
OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use in a prefilled pen. The label identifies the active ingredient semaglutide and the labeler A-S Medication Solutions. The image shows drug name, dosage strength, and usage instructions in black text on a yellow and white background.*
FDA Label Image

Image_122 (Image 08)

Image_122 (Image 08)
An instructional diagram of the OZEMPIC pen injection device and NovoFine Plus needle components. It labels parts of the pen including the pen cap, pen window, dose counter, dose pointer, dose selector, dose button, expiration date area, and features of the dose display such as the flow check symbol and dashed line. The needle assembly parts are also identified: outer needle cap, inner needle cap, needle, and paper tab.*
FDA Label Image

Image_123 (Image 09)

Image_123 (Image 09)
An instructional illustration showing hands manipulating a pen injector, likely demonstrating how to use or prepare the device for a subcutaneous injection. The image contains step-by-step visual guidance related to injection technique, consistent with patient usage instructions for an injectable drug like OZEMPIC (semaglutide).*
FDA Label Image

Image_124 (Image 10)

Image_124 (Image 10)
An instructional illustration showing a hand holding an injection pen device, likely for subcutaneous administration. The image focuses on the grip and preparation of the injection pen, without visible branding or text.*
FDA Label Image

Image_125 (Image 11)

Image_125 (Image 11)
An instructional illustration showing a close-up of a hand preparing a subcutaneous injection using a pen device. The image depicts an arrow indicating the removal of a protective cap or needle cover from the pen, relevant to the administration of OZEMPIC (semaglutide) injection solution.*
FDA Label Image

Image_126 (Image 12)

Image_126 (Image 12)
An instructional diagram showing a hand holding and preparing an injection pen, likely for a subcutaneous injection. The image focuses on the pen device with a dial relative to the plunger mechanism, suggesting preparation or dose setting of the medication injection device.*
FDA Label Image

Image_127 (Image 13)

Image_127 (Image 13)
An instructional illustration depicting the preparation of a subcutaneous injection. It shows a hand holding a syringe and using a vial or pen device, indicating the step of attaching or drawing medication, relevant to injectable solutions like Ozempic (semaglutide).*
FDA Label Image

Image_128 (Image 14)

Image_128 (Image 14)
An instructional illustration showing hands preparing a drug injection. It depicts the process of attaching a needle to a syringe or pen injector, indicated by an arrow guiding the step. This image is related to subcutaneous injection, relevant to the OZEMPIC injection solution.*
FDA Label Image

Image_129 (Image 15)

Image_129 (Image 15)
The image shows the front label of OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use. The label includes the proprietary name OZEMPIC in large letters, mentions the concentration 2.68 mg/mL, and identifies semaglutide as the active ingredient. The labeler is A-S Medication Solutions. The packaging indicates it is a human prescription drug.*
FDA Label Image

Image_flow_check_5 (Image 16)

Image_flow_check_5 (Image 16)
OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use in a pre-filled pen. The label includes the proprietary name OZEMPIC and the active ingredient semaglutide. The product is labeled by A-S Medication Solutions with NDC 50090-6051. The label also contains barcodes and usage instructions visible on the pen.*
FDA Label Image

Image_130 (Image 17)

Image_130 (Image 17)
An instructional diagram showing two hands holding a pen-like injection device. The illustration highlights the flow check symbol on the device with a label pointing to it, indicating where to check for proper flow before use.*
FDA Label Image

Image_131 (Image 18)

Image_131 (Image 18)
An instructional illustration showing a hand holding a semaglutide injection pen labeled OZEMPIC. The diagram depicts the pen with a cap being removed, indicated by an upward arrow, demonstrating how to prepare the injection device for subcutaneous use.*
FDA Label Image

Image_132 (Image 19)

Image_132 (Image 19)
The image shows a carton of OZEMPIC injection, solution for subcutaneous use, containing semaglutide at a strength of 2.68 mg/mL. The packaging features the OZEMPIC brand name prominently, with active ingredient and strength indicated. The labeler is A-S Medication Solutions, and the box is designed for a prescription human drug product.*
FDA Label Image

Image_dose_counter_5 (Image 20)

Image_dose_counter_5 (Image 20)
OZEMPIC 2.68 mg/mL injection solution for subcutaneous use in a prefilled pen injector. The label displays the product name, strength, dosage form, and the labeler A-S Medication Solutions. The pen is primarily white with orange and gray labeling details.*
FDA Label Image

Image_133 (Image 21)

Image_133 (Image 21)
An instructional diagram showing how to select the 1 mg dose on a semaglutide injection pen. The illustration highlights the pen dose selector turning until the dashed line aligns with the 1 mg dose marking, indicating the correct dose is selected.*
FDA Label Image

Image_134 (Image 22)

Image_134 (Image 22)
OZEMPIC 2.68 mg/mL injection, solution in a 1.5 mL cartridge for subcutaneous use. The label specifies the A-S Medication Solutions as the labeler and includes the NDC 50090-6051. The cartridge is part of a pen-type delivery system with a visible dose window and safety cap.*
FDA Label Image

Image_135 (Image 23)

Image_135 (Image 23)
Instructional diagram showing a step to stop and remove the dose counter label on an Ozempic injection pen. The image highlights holding and pulling the dose counter sticker to complete the preparation of the pen for subcutaneous injection.*
FDA Label Image

Image_136 (Image 24)

Image_136 (Image 24)
An anatomical illustration showing front and back views of a human body with marked locations on the abdomen and thigh, likely indicating recommended injection sites for a subcutaneous medication.*
FDA Label Image

Image_137 (Image 25)

Image_137 (Image 25)
An instructional diagram showing a hand holding a pen-like injection device with the thumb pressing down on the plunger. A downward arrow indicates the direction of injection. The illustration is intended to guide proper use of the injection device for subcutaneous administration.*
FDA Label Image

Image_138 (Image 26)

Image_138 (Image 26)
Instructional illustration showing a hand holding an Ozempic injection pen with an arrow pointing downward, indicating the direction to press the injection button. This depicts the subcutaneous injection process for Ozempic (semaglutide) 2.68 mg/mL solution.*
FDA Label Image

Image_139 (Image 27)

Image_139 (Image 27)
An instructional illustration showing a hand holding a pen-like injection device. A speech bubble indicates counting slowly from 1 to 6, likely demonstrating the method to administer a subcutaneous injection dose carefully and steadily.*
FDA Label Image

Image_140 (Image 28)

Image_140 (Image 28)
An instructional illustration showing a close-up of an injection pen with a blue cap being removed. An arrow points upward, indicating the direction to pull off the cap, for preparing the injection pen for use.*
FDA Label Image

Image_141 (Image 29)

Image_141 (Image 29)
OZEMPIC 2.68 mg/mL injection solution for subcutaneous use in a 1.5 mL pre-filled pen. The packaging is primarily white with purple accents and includes the A-S Medication Solutions labeler name. The vial is visible inside the box.*
FDA Label Image

Image_142 (Image 30)

Image_142 (Image 30)
An instructional diagram showing a hand removing or twisting the cap from the top of a pen-style injection device, indicated by a blue arrow pointing upward and to the left. The image demonstrates the first step in preparing the injection device for use.*
FDA Label Image

Image_143 (Image 31)

Image_143 (Image 31)
Illustration showing a step for using a medication vial, depicting an injection needle being inserted into the vial's rubber stopper. This image likely demonstrates preparation or extraction of medication from the vial.*
FDA Label Image

Image_144 (Image 32)

Image_144 (Image 32)
An instructional illustration depicting hands preparing an injection pen device, demonstrating how to attach or adjust a component of the pen for administering a subcutaneous injection. The image uses blue and white colors and includes a corner marked with the letter 'R'.*
FDA Label Image

Image_145 (Image 33)

Image_145 (Image 33)
An instructional diagram showing the connection of two components, likely a needle or cap being attached or detached from a pen device. The image uses arrows to indicate the direction of movement for proper assembly or disassembly.*
FDA Label Image

Image_146 (Image 34)

Image_146 (Image 34)
OZEMPIC 2.68 mg/mL injection solution in a 1.5 mL pre-filled pen pack, labeled for subcutaneous use. The packaging displays the A-S Medication Solutions labeler name and the National Drug Code 50090-6051. The carton is primarily white and orange with black text.*
FDA Label Image

Image_147 (Image 35)

Image_147 (Image 35)
OZEMPIC 2.68 mg/mL injection solution in a glass vial with a blue and transparent plastic cap. The label shows the product name, semaglutide as the active ingredient, dosage form as injection, and route as subcutaneous. The vial is labeled by A-S Medication Solutions.*
FDA Label Image

Image_148 (Image 36)

FDA Label Image

Image_149 (Image 37)

FDA Label Image

Image_61 (Image 38)

Image_61 (Image 38)
OZEMPIC injection, solution, 2.68 mg/mL, shown in a clear glass vial with a white and gradient orange cap. The vial label displays the product name OZEMPIC prominently in orange, the active ingredient semaglutide, concentration, and usage instructions including instructions for subcutaneous administration. The labeler is A-S Medication Solutions and the vial appears intended for single patient use.*
FDA Label Image

Image_62 (Image 39)

Image_62 (Image 39)
An instructional diagram of the OZEMPIC pen and NovoFine Plus needle components, showing parts such as the pen cap, pen window with expiration and lot number labels, dose counter, dose pointer, dose selector, and dose button. Also includes the outer and inner needle caps, needle, paper tab, flow check symbol, and dashed line guide for dose adjustment.*
FDA Label Image

Image_63 (Image 40)

Image_63 (Image 40)
An instructional illustration showing hands preparing a pen injector device, likely for subcutaneous injection. The image focuses on the removal or placement of a pen cap, demonstrating proper handling steps for use with the medication.*
FDA Label Image

Image_64 (Image 41)

Image_64 (Image 41)
An instructional illustration showing a hand holding a subcutaneous injection pen, likely demonstrating the preparation or administration of an injection, relevant to the use of OZEMPIC (semaglutide) injection solution.*
FDA Label Image

Image_65 (Image 42)

Image_65 (Image 42)
An instructional illustration showing a hand holding a device while removing or inserting a component by pulling it off in the direction of an arrow pointing to the left. The image appears to demonstrate part of the preparation or use process for a subcutaneous injection device, likely related to OZEMPIC semaglutide injection.*
FDA Label Image

Image_66 (Image 43)

Image_66 (Image 43)
An instructional illustration showing the step of attaching or preparing a syringe for injection, likely related to subcutaneous injection use. The image depicts a hand holding a syringe and interacting with the needle cap or protective cover.*
FDA Label Image

Image_67 (Image 44)

Image_67 (Image 44)
An instructional illustration depicting a person preparing a subcutaneous injection. The image shows hands holding a syringe-like device and a pen injector, demonstrating the process of removing the cap or attaching the needle before injection. This is relevant for the administration of subcutaneous injection solutions such as OZEMPIC (semaglutide) 2.68 mg/mL.*
FDA Label Image

Image_68 (Image 45)

Image_68 (Image 45)
An instructional illustration demonstrating how to prepare a subcutaneous injection using a syringe and vial, showing the insertion of the needle into the vial to draw medication.*
FDA Label Image

Image_69 (Image 46)

Image_69 (Image 46)
OZEMPIC 2.68 mg/mL injection solution in a 3 mL pre-filled pen. The label includes the generic name semaglutide and indicates it is for subcutaneous use. The packaging shows the labeler as A-S Medication Solutions with Product NDC 50090-6051.*
FDA Label Image

Image_flow_check_3 (Image 47)

Image_flow_check_3 (Image 47)
OZEMPIC injection, solution 2.68 mg/mL label by A-S Medication Solutions. It is a subcutaneous injectable human prescription drug. The label includes the product name OZEMPIC prominently, the active ingredient semaglutide, and details such as dosage form and route of administration. The label features a red and white color scheme with clear font for legibility.*
FDA Label Image

Image_70 (Image 48)

Image_70 (Image 48)
Instructional diagram showing a finger pressing a button on a device labeled with the letter 'G'. A text box at the bottom indicates the flow check symbol is selected, illustrating part of the usage process for the Ozempic semaglutide injection pen device.*
FDA Label Image

Image_71 (Image 49)

Image_71 (Image 49)
An instructional illustration showing a hand holding a device with a cap, with an arrow pointing upward, suggesting the removal or lifting of the cap from the device. The image appears related to the use of an injection pen or similar medical device.*
FDA Label Image

Image_72 (Image 50)

Image_72 (Image 50)
OZEMPIC 2.68 mg/mL injection solution for subcutaneous use displayed in a clear glass vial with a white cap and a label that includes the product name, strength, and manufacturer, A-S Medication Solutions.*
FDA Label Image

Image_dose_counter_3 (Image 51)

Image_dose_counter_3 (Image 51)
OZEMPIC injection, solution, 2.68 mg/mL in a clear vial with a black cap labeled by A-S Medication Solutions. The vial contains a transparent liquid and features text indicating the product name and strength.*
FDA Label Image

Image_73 (Image 52)

Image_73 (Image 52)
An instructional diagram showing how to select a dosage on a pen injector. The image highlights the dialed line with example doses of 0.25 mg (selected) and 0.5 mg (not selected) to guide users in setting the injection dose for a medication.*
FDA Label Image

Image_74 (Image 53)

Image_74 (Image 53)
The image shows a clear glass vial labeled OZEMPIC semaglutide injection, solution with a strength of 2.68 mg/mL. The vial has a metal crimped cap and a rubber stopper. The label includes the labeler name A-S Medication Solutions and the product NDC 50090-6051. The solution inside the vial is colorless.*
FDA Label Image

Image_75 (Image 54)

Image_75 (Image 54)
An instructional illustration showing a hand holding a semaglutide injection pen labeled OZEMPIC. The pen displays a dosage window with the example dose stopped at 0.25 mg, demonstrating how to select and administer the dose using the pen for subcutaneous injection.*
FDA Label Image

Image_76 (Image 55)

Image_76 (Image 55)
An instructional anatomical diagram showing the recommended subcutaneous injection sites for administering a solution injection. The diagram depicts the front and back views of a human torso and legs, highlighting areas such as the abdomen, thighs, and upper arm as injection sites.*
FDA Label Image

Image_77 (Image 56)

Image_77 (Image 56)
An instructional illustration showing a hand holding a pen-like injection device, positioned for subcutaneous injection into the skin with a downward arrow indicating the injection direction.*
FDA Label Image

Image_78 (Image 57)

Image_78 (Image 57)
An instructional diagram illustrating how to hold and operate a pen-style injection device for subcutaneous administration. It shows a hand grasping the device with the thumb positioned to press down on the injection button, demonstrating the proper technique for use.*
FDA Label Image

Image_79 (Image 58)

Image_79 (Image 58)
An instructional illustration showing a hand holding an injection pen with a speech bubble indicating to count slowly: 1-2-3-4-5-6. The image suggests a step in the usage or administration process for the product.*
FDA Label Image

Image_80 (Image 59)

Image_80 (Image 59)
An instructional illustration showing the upper part of an injection device or pen with a needle attached. An upward-pointing arrow indicates the needle is being pulled off or removed from the injection device, suggesting a step in preparing the pen for subcutaneous injection.*
FDA Label Image

Image_81 (Image 60)

Image_81 (Image 60)
OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use, displayed in a clear glass vial with a gray rubber stopper and a blue flip-off cap. The vial label includes product name, strength, and manufacturer A-S Medication Solutions, with additional dosing and storage information partially visible.*
FDA Label Image

Image_82 (Image 61)

Image_82 (Image 61)
Instructional illustration showing how to remove the protective cap from a prefilled injection pen or syringe. The image depicts a hand pulling the cap upward and away from the device, indicating preparation of the injection for use.*
FDA Label Image

Image_83 (Image 62)

Image_83 (Image 62)
An instructional illustration showing the action of attaching or pressing a cap with a downward arrow onto the top of a circular container or vial, indicating a step for use or assembly related to the product.*
FDA Label Image

Image_84 (Image 63)

Image_84 (Image 63)
An instructional illustration showing a person holding a pen-like device, demonstrating how to properly attach or prepare a needle for injection. The image focuses on hand placement and needle handling, relevant for injection administration guidance.*
FDA Label Image

Image_85 (Image 64)

Image_85 (Image 64)
An instructional diagram demonstrating how to attach a needle to a pen-style injection device, likely for the subcutaneous injection of Ozempic (semaglutide) solution. The arrows indicate the steps for connecting the needle to the device.*
FDA Label Image

Image_86 (Image 65)

Image_86 (Image 65)
OZEMPIC 2.68 mg/mL injection solution in a subcutaneous injection pen by A-S Medication Solutions. The label includes the proprietary name OZEMPIC and generic name semaglutide, with dosage strength clearly displayed. The product NDC is 50090-6051.*
FDA Label Image

Image_87 (Image 66)

Image_87 (Image 66)
The image shows a carton of OZEMPIC injection, solution 2.68 mg/mL by A-S Medication Solutions. The packaging is primarily white with blue and purple text and design elements, including the OZEMPIC logo prominently displayed. It indicates the product is for subcutaneous use.*
FDA Label Image

Image_88 (Image 67)

FDA Label Image

Image_89 (Image 68)

FDA Label Image

Image_91 (Image 73)

Image_91 (Image 73)
OZEMPIC injection, solution, 2.68 mg/mL by A-S Medication Solutions, displayed in a single-use auto-injector pen. The label shows the proprietary name OZEMPIC prominently with active ingredient semaglutide and strength indicated. The product is for subcutaneous use and the package includes directions and dosage information visible on the pen body.*
FDA Label Image

Image_92 (Image 74)

Image_92 (Image 74)
Illustration showing components and features of the OZEMPIC pen and NovoFine Plus needle. Labeled parts include pen cap, pen window, dose counter, dose pointer, dose selector, dose button, outer needle cap, inner needle cap, needle, paper tab, flow check symbol, and a dashed line used to guide dose selection.*
FDA Label Image

Image_93 (Image 75)

Image_93 (Image 75)
An instructional illustration showing two hands holding a device, with an arrow indicating a twisting or turning motion on a cap or knob. The image suggests a step in preparing or using the injection device for Ozempic (semaglutide) subcutaneous solution.*
FDA Label Image

Image_94 (Image 76)

Image_94 (Image 76)
An illustration showing a partial view of a blue and white injection pen device with the needle end exposed. The image highlights the subcutaneous injection solution dosage form of OZEMPIC (semaglutide).*
FDA Label Image

Image_95 (Image 77)

Image_95 (Image 77)
An instructional illustration showing a person using their hands to remove or twist off a cap or cover from a small object, indicated by an arrow pointing to the left. This may relate to preparation or usage steps for the OZEMPIC injection device.*
FDA Label Image

Image_96 (Image 78)

Image_96 (Image 78)
An instructional illustration showing a hand holding an injection pen, focusing on gripping the pen's upper portion near the needle cap. The image is labeled with the letter 'D' in the upper left corner, indicating a step in usage.*
FDA Label Image

Image_97 (Image 79)

Image_97 (Image 79)
An instructional diagram showing a close-up of a hand holding and aligning parts of a medical injection device, indicating the connection or assembly of components, related to subcutaneous injection use.*
FDA Label Image

Image_98 (Image 80)

Image_98 (Image 80)
An instructional illustration showing a hand peeling a protective cap from the tip of a pen-style injection device, indicating preparation steps before subcutaneous injection.*
FDA Label Image

Image_99 (Image 81)

Image_99 (Image 81)
Packaging label of OZEMPIC 2.68 mg/mL injection solution for subcutaneous use by A-S Medication Solutions. The label displays dosing information, directions for use, and warnings, primarily in English with additional text in Spanish. The label includes a barcode, lot number, expiration date, and usage instructions emphasizing proper handling and storage of the product.*
FDA Label Image

Image_flow_check_4 (Image 82)

Image_flow_check_4 (Image 82)
The image shows the front label of an OZEMPIC injection solution. The label displays the proprietary name OZEMPIC, the generic name semaglutide, and the strength 2.68 mg/mL. The dosage form is subcutaneous injection. The labeler is A-S Medication Solutions. The text includes drug information and branding details on a white background with purple and gray design elements.*
FDA Label Image

Image_100 (Image 83)

Image_100 (Image 83)
An instructional illustration showing hands holding a pen-like device used for subcutaneous injection. The image highlights the 'Flow check symbol selected' near the device's dose window, indicating a step in preparing the injection to verify proper flow before use.*
FDA Label Image

Image_101 (Image 84)

Image_101 (Image 84)
An instructional illustration showing a hand holding an injection pen, presumably for OZEMPIC (semaglutide) injection, solution 2.68 mg/mL. The image highlights twisting or unlocking the pen cap in an upward direction, as indicated by an arrow. The instruction likely relates to preparing the subcutaneous injection pen for use.*
FDA Label Image

Image_102 (Image 85)

Image_102 (Image 85)
Packaging label for OZEMPIC (semaglutide) injection, solution, 2.68 mg/mL, by A-S Medication Solutions. The label shows dosage form as subcutaneous injection and includes storage and usage instructions, barcode, and other regulatory markings on a white and green background.*
FDA Label Image

Image_dose_counter_4 (Image 86)

Image_dose_counter_4 (Image 86)
OZEMPIC 2.68 mg/mL injection, solution in a single-dose pen. The label shows the product name OZEMPIC, the active ingredient semaglutide, and strength of 2.68 mg/mL. It is a subcutaneous injection supplied by A-S Medication Solutions. The packaging includes instructions and dosage information for the pen injector device.*
FDA Label Image

Image_103 (Image 87)

Image_103 (Image 87)
An instructional illustration showing a person holding an Ozempic injection solution pen, focusing on the dose selector window. The image highlights the dashed line indicator and the number "2 mg selected" to demonstrate dose selection on the pen's display.*
FDA Label Image

Image_104 (Image 88)

Image_104 (Image 88)
OZEMPIC 2.68 mg/mL injection, solution in a subcutaneous injection form, manufactured by A-S Medication Solutions. The label includes the proprietary name, active ingredient semaglutide, concentration, and drug type, displayed on a white and yellow vial label with black text.*
FDA Label Image

Image_105 (Image 89)

Image_105 (Image 89)
Illustration showing the dose counter window of an OZEMPIC (semaglutide) 2.68 mg/mL injection pen. The image highlights the dose counter stopped at 2 mg left, indicating the remaining dose in the pen. This visual aids in understanding how to read the dose counter on the subcutaneous injection device.*
FDA Label Image

Image_106 (Image 90)

Image_106 (Image 90)
An instructional illustration showing front and back views of a human torso, highlighting possible subcutaneous injection sites. This diagram is typically used to guide proper injection locations for subcutaneous drugs like OZEMPIC (semaglutide) injection.*
FDA Label Image

Image_107 (Image 91)

Image_107 (Image 91)
An instructional illustration showing a hand holding a prefilled injection pen vertically above an injection site. A downward arrow indicates the direction to inject, suggesting the proper technique for subcutaneous administration of the medication.*
FDA Label Image

Image_108 (Image 92)

Image_108 (Image 92)
An instructional illustration showing a hand holding a prefilled injection pen labeled OZEMPIC (semaglutide) 2.68 mg/mL. The image demonstrates the step of pressing the pen to deliver the dose, indicated by a downward arrow. A dose display window shows the selected mg amount.*
FDA Label Image

Image_109 (Image 93)

Image_109 (Image 93)
An instructional illustration showing a hand holding an injection pen against the skin with a speech bubble containing a counting sequence "1-2-3-4-5-6". The image appears to demonstrate the correct time to hold the injection pen after inserting the needle for a subcutaneous injection.*
FDA Label Image

Image_110 (Image 94)

Image_110 (Image 94)
An instructional diagram showing a subcutaneous injection pen with an upward-pointing arrow, indicating the direction for removing or handling the pen's cap or needle cover.*
FDA Label Image

Image_111 (Image 95)

Image_111 (Image 95)
OZEMPIC 2.68 mg/mL injection solution for subcutaneous use in a 3 mL cartridge. The packaging label shows the product name, active ingredient semaglutide, strength 2.68 mg/mL, and labeler A-S Medication Solutions. The label also includes usage instructions and barcode information.*
FDA Label Image

Image_112 (Image 96)

Image_112 (Image 96)
Illustration showing a hand twisting the cap of an injection pen, indicating how to remove or attach the cap prior to use.*
FDA Label Image

Image_113 (Image 97)

Image_113 (Image 97)
An instructional illustration showing a vial with its stopper being punctured or accessed by a needle or device from above, indicated by a downward arrow. This likely demonstrates how to prepare or draw medication from a vial.*
FDA Label Image

Image_114 (Image 98)

Image_114 (Image 98)
An instructional illustration showing hands holding a pen-like injection device. The illustration depicts twisting or removing a cap from the device, indicated by an arrow pointing in a clockwise direction, demonstrating part of the preparation or use process for the injection.*
FDA Label Image

Image_115 (Image 99)

Image_115 (Image 99)
An instructional illustration depicting the connection of a pen needle to the pen device for injection. The diagram shows an arrow indicating the direction to attach the needle to the pen, relevant to the subcutaneous injection use of the product.*
FDA Label Image

Image_116 (Image 100)

Image_116 (Image 100)
OZEMPIC 2.68 mg/mL injection, solution for subcutaneous use, displayed in a Vial with a purple cap. The label shows the brand name, dosage strength, and NDC 50090-6051, labeled by A-S Medication Solutions.*
FDA Label Image

Image_117 (Image 101)

Image_117 (Image 101)
OZEMPIC 2.68 mg/mL injection solution label, a human prescription drug by A-S Medication Solutions. The label includes product name, generic name semaglutide, strength, dosage form as injection, and route of administration subcutaneous. It also displays the product NDC 50090-6051 and other regulatory and identification details.*
FDA Label Image

Image_118 (Image 104)

Image_118 (Image 104)
An instructional diagram of the OZEMPIC pen and NovoFine Plus needle components. It details parts of the OZEMPIC pen injector including the pen cap, pen window, dose counter, dose pointer, dose selector, and dose button. The needle assembly is shown with outer needle cap, inner needle cap, needle, and paper tab. Additional features such as expiration date location and a flow check symbol with a dashed line guide are also labeled.*
FDA Label Image

Image_119 (Image 105)

Image_119 (Image 105)
An instructional illustration showing two hands pulling apart a device, likely demonstrating how to separate or prepare a component of the OZEMPIC injection pen for subcutaneous administration.*
FDA Label Image

Label Image (Lbl500906051)

Label Image (Lbl500906051)
OZEMPIC (semaglutide) 2.68 mg/mL injection, solution in a prefilled pen. The label includes dosage and storage instructions, emphasizing refrigeration but not freezing, and notes about dispensing the pen with a branded needle pack. Labeler is A-S Medication Solutions, Libertyville, Illinois.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.